Literature DB >> 32437562

Sensitizing Burkitt lymphoma to EBV-CTLs.

Helen E Heslop1.   

Abstract

Entities:  

Year:  2020        PMID： 32437562      PMCID： PMC7243150          DOI： 10.1182/blood.2020005492

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

3.  Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease.

Authors:  Sajida Kazi; Abhinav Mathur; Gwen Wilkie; Kirsty Cheal; Richard Battle; Neil McGowan; Neil Fraser; Emily Hargreaves; David Turner; John D M Campbell; Marc Turner; Mark A Vickers
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

4.  Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.

Authors:  Vanya Icheva; Simone Kayser; Daniel Wolff; Sebastian Tuve; Christina Kyzirakos; Wolfgang Bethge; Johann Greil; Michael H Albert; Wolfgang Schwinger; Michaela Nathrath; Michael Schumm; Stefan Stevanovic; Rupert Handgretinger; Peter Lang; Tobias Feuchtinger
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

5.  Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.

Authors:  Susan Prockop; Ekaterina Doubrovina; Stephanie Suser; Glenn Heller; Juliet Barker; Parastoo Dahi; Miguel A Perales; Esperanza Papadopoulos; Craig Sauter; Hugo Castro-Malaspina; Farid Boulad; Kevin J Curran; Sergio Giralt; Boglarka Gyurkocza; Katharine C Hsu; Ann Jakubowski; Alan M Hanash; Nancy A Kernan; Rachel Kobos; Guenther Koehne; Heather Landau; Doris Ponce; Barbara Spitzer; James W Young; Gerald Behr; Mark Dunphy; Sofia Haque; Julie Teruya-Feldstein; Maria Arcila; Christine Moung; Susan Hsu; Aisha Hasan; Richard J O'Reilly
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 6.  The immunology of Epstein-Barr virus-induced disease.

Authors:  Graham S Taylor; Heather M Long; Jill M Brooks; Alan B Rickinson; Andrew D Hislop
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

7.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

8.  Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.

Authors:  Tanner Dalton; Ekaterina Doubrovina; Dmitry Pankov; Raymond Reynolds; Hanna Scholze; Annamalai Selvakumar; Teresa Vizconde; Bhumesh Savalia; Vadim Dyomin; Christoph Weigel; Christopher C Oakes; Alicia Alonso; Olivier Elemento; Heng Pan; Jude M Phillip; Richard J O'Reilly; Benjamin E Gewurz; Ethel Cesarman; Lisa Giulino-Roth
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

9.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Authors:  Catherine M Bollard; Stephen Gottschalk; Vicky Torrano; Oumar Diouf; Stephanie Ku; Yasmin Hazrat; George Carrum; Carlos Ramos; Luis Fayad; Elizabeth J Shpall; Barbara Pro; Hao Liu; Meng-Fen Wu; Daniel Lee; Andrea M Sheehan; Youli Zu; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

10.  Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.

Authors:  Whay-Kuang Chia; Marissa Teo; Who-Whong Wang; Bernett Lee; Soo-Fan Ang; Wai-Meng Tai; Chit-Lai Chee; Joanna Ng; Rebecca Kan; Wan-Teck Lim; Sze-Huey Tan; Whee-Sze Ong; Yin-Bun Cheung; Eng-Huat Tan; John E Connolly; Stephen Gottschalk; Han-Chong Toh
Journal:  Mol Ther       Date:  2013-10-17       Impact factor: 11.454
  10 in total
  2 in total

1.  Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis.

Authors:  Lihua Dong; Jingjing Huang; Peng Zu; Jing Liu; Xue Gao; Jianwei Du; Yufu Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 2.  How Does Epstein-Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers?

Authors:  Yuxi Wen; Huan Xu; Juan Han; Runming Jin; Hongbo Chen
Journal:  Front Cell Infect Microbiol       Date:  2022-02-23       Impact factor: 5.293
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.